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Summary
Background A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart 
disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment 
of rheumatoid arthritis reduces systemic and articular inﬂ ammation. However, whether IL6R blockade also reduces 
risk of coronary heart disease is unknown.
Methods Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the 
gene IL6R to evaluate the likely eﬃ  cacy and safety of IL6R inhibition for primary prevention of coronary heart disease. 
We compared genetic ﬁ ndings with the eﬀ ects of tocilizumab reported in randomised trials in patients with 
rheumatoid arthritis.
Findings In 40 studies including up to 133 449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous 
IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration 
(increase per allele 9·45%, 95% CI 8·34–10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 
95% CI 7·31–9·38) and ﬁ brinogen concentrations (decrease per allele 0·85%, 95% CI 0·60–1·10). This pattern of 
eﬀ ects was consistent with IL6R blockade from infusions of tocilizumab (4–8 mg/kg every 4 weeks) in patients with 
rheumatoid arthritis studied in randomised trials. In 25 458 coronary heart disease cases and 100 740 controls, the 
IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 
95% CI 0·93–0·97, p=1·53×10–⁵).
Interpretation On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in 
development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of 
coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in popu lations 
could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and 
targets for new therapeutic uses.
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Introduction
Inﬂ ammation is implicated in atherogenesis,1 but a 
causal association with a speciﬁ c inﬂ ammatory mediator 
has not been established. Interleukin 6, an inﬂ ammatory 
cytokine produced mainly by T cells, macrophages, and 
adipocytes, promotes inﬂ ammatory responses via the 
membrane-bound or circulating soluble interleukin-6 
receptor (IL6R) on monocytes, hepatocytes, and endo-
thelial cells2 (appendix p 26). Similarly to C-reactive 
protein and ﬁ brinogen, whose synthesis is stimulated by 
IL6R signalling, high circulating concen trations of 
interleukin 6 were associated with increased risk of 
coronary heart disease events in prospective observational 
studies.3–5 Despite exclusion of C-reactive protein and 
ﬁ brinogen as causal mediators, on the basis of mendelian 
randomisation studies6,7 IL6R signalling could be an 
important therapeutic target for prevention of coronary 
heart disease.
Tocilizumab, a monoclonal antibody that blocks 
both membrane-bound and circulating IL6R, has anti-
inﬂ ammatory actions that extend beyond reductions 
in C-reactive protein and ﬁ brinogen concentrations.8,9 
Tocilizumab is licensed for treatment of rheumatoid 
arthritis10–12 and has been shown to reduce articular 
inﬂ ammation and promote disease remission.13,14 
However, adequately powered, long-term trials of 
tocilizumab on risk of cardiovascular disease have not 
yet been undertaken.
See Online for appendix
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Randomised trials in patients with rheumatoid arth ritis 
revealed that tocilizumab increases total, HDL, and LDL 
cholesterol and triglycerides,15,16 yet whether these lipid 
changes are on-target or oﬀ -target eﬀ ects of tocilizumab, 
or whether they reﬂ ect a non-speciﬁ c alleviation of 
suppressed inﬂ ammation as reported with other anti-
inﬂ ammatory rheumatoid arthritis treat ments, is 
uncertain.17 Whether the potentially proathero genic 
increases in LDL cholesterol are oﬀ set by potentially 
antiatherogenic eﬀ ects of reduced inﬂ ammation, or by 
the increase in HDL cholesterol, is also uncertain. Recog-
nising that patients with rheumatoid arthritis are at 
increased risk of cardiovascular disease by virtue of their 
autoimmune disease and related vascular patho logical 
changes18 and that tocilizumab is intended as a long-term 
treatment, the US Food and Drug Admin istration has 
mandated randomised controlled trials examining the 
cardiovascular eﬀ ects of tocilizumab in patients with 
rheumatoid arthritis12 (NCT01331837 and NCT00535782). 
However, these ongoing trials will not answer the question 
of whether IL6R blockade will modify risk of coronary 
heart disease in the general population.
A recently developed extension to the mendelian 
randomisation paradigm19,20—mendelian randomisation 
for drug target validation—uses variants in a gene 
encoding a drug target to proﬁ le the mechanism-based 
eﬀ ects of pharmacological modiﬁ cation of that target and 
to distinguish on-target from oﬀ -target actions.21 By pro-
viding randomised evidence for the likely eﬀ ectiveness of 
a new treatment in human beings without the potential 
risks of exposure to a novel drug or the cost of a randomised 
trial, this approach could aid prioritisation of targets for 
drug development. We applied mendelian randomisation 
to examine whether IL6R modulation is likely to reduce 
risk of coronary heart disease in the general population. 
We ﬁ rst evaluated the legitimacy of single nucleotide 
polymorphisms (SNPs) in the IL6R gene (Ch1q21.3) as 
indicators of the mechanism-based eﬀ ect of pharma-
cological interference in IL6R signalling (appendix p 26). 
We then undertook a large-scale collaborative genetic 
association analysis of IL6R variants with coronary heart 
disease events and stroke and examined safety endpoints, 
including infections and common cancers.
Methods
Treatment trials and other studies of tocilizumab
Following PRISMA guidelines22 (appendix p 28), we 
searched Medline using PubMed for randomised trials, 
cohorts, or meta-analyses comparing tocilizumab (4 or 
8 mg/kg) with placebo in human beings (appendix 
pp 1, 7). Details of extracted data and methods used to 
synthesise and combine estimates of trial results are 
reported in the appendix.
Genetic association studies
We included individual participant data for up to 
133 449 participants of European ancestry from 40 studies 
(appendix pp 1–7, 11–12). Data from this de-novo analysis 
were pooled with previously published infor mation about 
the association of IL6R variants with clinical events. We 
gathered phenotypic data across several studies (appen-
dix pp 13–14) for analysis of associations between IL6R 
genotype and interleukin 6, C-reactive protein, ﬁ brinogen, 
and major blood lipid fractions.
The primary event endpoint for the genetic analysis 
was all fatal and non-fatal coronary heart disease events 
(consisting of myocardial infarction and coronary 
revascularisation; appendix pp 15–16). Secondary eﬃ  cacy 
endpoints were all-cause stroke, and all fatal and non-
fatal cardiovascular disease (consisting of myocardial 
infarction, coronary revascularisation, and stroke). These 
disease outcomes are analogous to the eﬃ  cacy outcomes 
in an orthodox randomised trial.
On the basis of published associations of interleukin-6 
concentrations with disease outcomes other than coronary 
heart disease, safety endpoints reported in tocilizumab 
trials, and standard safety endpoints for cardiovascular 
intervention trials, we investigated the association of IL6R 
variants with all-site cancer, major cancer subtypes (breast 
and colorectal), respiratory infection, and liver enzyme 
concentrations. We obtained safety data from de-novo 
investigations of IL6R variants, from estimates of the 
association of any safety outcome with IL6R variants 
reported in the National Human Genome Research 
Institute genome-wide association study catalogue,23 and 
from other reported associations of published genome-
wide association studies (appendix p 17). We also 
estimated the association between IL6R variants and 
other established risk factors for cardiovascular disease 
including blood pressure and type 2 diabetes.
SNP selection, genotyping, and quality control
Using the HumanCVD BeadChip,24 we genotyped 
4489 individuals of European ancestry in the Whitehall II 
study. From the 42 SNPs located within 55 kb of IL6R 
present on the array, we selected a subset of SNPs for 
further analysis in other datasets on the basis of four 
factors: (1) the statistical strength of association with 
interleukin-6 concentration; (2) linkage disequilibrium 
(LD) between SNPs in populations of European ancestry 
using Human HapMap Phase 3 Build 36 data, to reduce 
redundancy; (3) previous disease and biomarker asso-
ciations of SNPs in this region (appendix p 27); and (4) a 
minor allele frequency (MAF) threshold of greater than 
0·3. Data were excluded if the allele call rate was less 
than 90% or the Hardy-Weinberg equilibrium (HWE) χ² 
p value was less than 0·001 in any study.
Statistical analysis
Genotypes were coded as 0, 1, and 2, indicating the 
number of variant allele copies. The analysis was done 
with an additive model suggested by IL6R associations 
with circulating interleukin-6 concentrations in the 
index Whitehall II Study. Owing to skewed distributions, 
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values of interleukin 6, C-reactive protein, ﬁ brinogen, 
and triglycerides were analysed on the natural log-
arithmic scale.
Using individual participant-level data, we estimated 
the mean diﬀ erence in interleukin 6, C-reactive protein, 
and ﬁ brinogen between genotype groups for each SNP. 
Additionally, for these inﬂ ammatory markers, the major 
lipid fractions, and other biomarkers, we ﬁ tted univariate 
linear regression models within each study to investigate 
evidence of a linear association between the biomarker 
and possession of each additional copy of the minor 
allele. All analyses were done within each study according 
to a common analysis plan implemented with a stand-
ardised Stata (version 11.1) program, adapted for SPSS and 
PLINK in some studies. Where possible, we repeated 
analyses in prespeciﬁ ed subgroups (appendix pp 5–6).
To assess association of SNPs with disease endpoints, 
we estimated unadjusted odds ratios (OR) per minor 
allele within each study using logistic regression models. 
In studies for which relevant data were available 
(27 studies, 97 300 participants), we estimated the 
per-allele OR for coronary heart disease events, stratiﬁ ed 
where appropriate by prespeciﬁ ed characteristics 
(appendix pp 5–6) within each study, and by study design. 
Within-study estimates were combined with inverse-
variance weighted ﬁ xed-eﬀ ects meta-analysis. We used 
I² to quantify between-study heterogeneity.25 In subgroup 
analyses, we tested for heterogeneity between strata 
using the meta-analysis χ² test for heterogeneity.
Role of the funding source
The funding sources had no role in study design, in the 
collection, analysis, and interpretation of data, in the 
writing of the report, or in the decision to submit for 
publication. The corresponding author (DIS) and co-
senior authors (ADH and JPC) had full access to all data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
We identiﬁ ed six short-term randomised trials 
(12–52 week duration) evaluating 4 mg/kg or 8 mg/kg 
tocilizumab in 2891 patients with rheumatoid arthritis 
(weighted mean age 52·3 years; 19% male; appendix 
p 28).8,9,26–29 C-reactive protein was the most widely 
reported inﬂ ammation marker and its weighted mean 
concentration at baseline was 28·2 (SD 1·9) mg/L. 
Tocilizumab treatment (4, 8, and 16 mg/kg in randomised 
Randomised trials of tocilizumab (8 mg/kg) Genetic studies (present analyses; per-allele eﬀ ect)
Number of 
individuals 
(trials)
Summary eﬀ ect (95% CI) p value Number of 
individuals 
(studies)
Summary eﬀ ect (95% CI) p value
Mean diﬀ erence
Interleukin 6 (pg/mL) 1446 (4) 28·89 (23·04 to 34·75) 4·10×10²² 29 838 (17) 0·09 (0·08 to 0·10)* 8·41×10⁶⁸
Soluble IL6R (ng/mL) 1465 (4) 529·87 (529·29 to 530·45) <1×10⁹⁵ 1454 (3) 14·87 (13·07 to 16·66) 2·69×10⁵⁹
C-reactive protein (mg/L) 3010 (6) –19·02 (–16·28 to –21·72) 2·37×10³⁷ 76 527 (30) –0·09 (–0·10 to –0·08)* 9·92×10⁵²
Fibrinogen (g/L) 108 (1) –2·50 to (–2·50 to –3·11) 7·14×10¹⁶ 52 667 (19) –0·009 (–0·011 to –0·006)* 3·25×10¹¹
Total cholesterol (mmol/L) 955 (4) 0·89 (0·78 to 0·99) 2·81×10⁴² 114 615 (33) 0·004 (–0·005 to 0·013) 0·37
HDL cholesterol (mmol/L) 616 (3) 0·12 (0·07 to 0·17) 4·02×10⁶ 105 439 (30) 0·002 (–0·001 to 0·006) 0·18
LDL cholesterol (mmol/L) 409 (1) 0·57 (0·45 to 0·69) 7·41×10²² 97 966 (28) –0·003 (–0·012 to 0·005) 0·45
Triglycerides ·· ·· ·· 105 656 (30) –0·002 (–0·006 to 0·002)* 0·42
Albumin (g/L) 108 (1) 6·00 (4·50 to 7·50) 6·55×10¹⁵ 5787 (3) 0·10 (0·01 to 0·20) 0·03
ESR (mm/h) 1658 (4) –30·49 (–27·83 to –33·14) 5·55×10⁹⁵ ·· ·· ··
Platelets (×10⁹/L) 108 (1) –1·27 (–1·66 to –0·88) 1·72×10¹⁰ 3274 (1) –0·76 (–4·33 to 2·81) 0·68
Serum amyloid A† 517 (2) –0·75 (–0·57 to –0·93) 1·28×10¹⁶ ·· ·· ··
Haemoglobin (g/L) 2072 (4) 12·7 (11·1 to 14·2) 1·96×10⁵⁶ 17 898 (4) 0·022 (0·002 to 0·043) 0·04
AST (U/L) ·· ·· ·· 7201 (4) 0·006 (–0·003 to 0·016) 0·20
Odds ratio
Triglycerides >5·7 mmol/L 1220 (1) 1·42 (0·42 to 4·42) 0·55 ·· ·· ··
ALT 3×ULN 2755 (4) 6·95 (3·58 to 13·50) 9·95×10⁹ ·· ·· ··
AST 3×ULN 2420 (3) 4·74 (1·66 to 13·62) 0·004 ·· ·· ··
Summary eﬀ ect is mean diﬀ erence (95% CI) for all biomarkers apart from triglycerides greater than 5·7 mmol/L (500 mg/L), ALT 3×ULN, and AST 3×ULN, for which estimates 
are odds ratio (95% CI). For tocilizumab, the mean diﬀ erence is for tocilizumab versus placebo and for the IL6R rs7529229 variant, the mean diﬀ erence is per minor allele. Trial 
data are for comparison of tocilizumab (8 mg/kg daily) and placebo groups at timepoints between 6 and 24 weeks (apart from C-reactive protein, which was taken at 8 weeks 
for all trials except one,9 which reported values at 52 weeks). IL6R=interleukin-6 receptor. ESR=erythrocyte sedimentation rate. ALT=alanine transaminase. ULN=upper limit 
of normal. AST=aspartate transaminase. *Mean diﬀ erence per minor allele on the loge scale represents proportional diﬀ erence in geometric mean. †For serum amyloid A, we 
could not harmonise units, thus the standardised mean diﬀ erence is presented.
Table: Summary eﬀ ects of tocilizumab (8 mg/kg) and the IL6R rs7529229 variant on inﬂ ammatory, lipid, hepatic, and haematological biomarkers
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or observational studies every 4 weeks) was associated 
with a dose-dependent reduction in C-reactive protein 
concentration (appendix p 29). The 8 kg/mg dose reduced 
ﬁ brinogen, increased interleukin 6 and soluble IL6R, and 
increased LDL and HDL cholesterol (table).
40 studies contributed genotype and phenotype data 
for the de-novo genetic analysis of IL6R SNPs from a 
total of 133 449 individuals with mean age at recruitment 
of 59 (range 26–75) years, of whom 49% were women. 
Additional characteristics of study participants are de-
scribed in appendix pp 11–16, 30–33. 12 of the 42 SNPs in 
the region of the IL6R locus on the HumanCVD 
BeadChip met chip-wide signiﬁ cance (p<1×10–⁵) for their 
association with circulating interleukin 6 in the Whitehall 
II study (appendix pp 20–21). We selected three SNPs 
(rs7529229, rs4845371, rs12740969) based on MAF greater 
than 0·3, β coeﬃ   cient greater than 0·9 log interleukin-6 
concen tration per allele, previously reported associations, 
and low-redundancy LD structure (appendix p 27). The 
rs7529229 variant was in strong LD (r²=0·92 in the 
Whitehall II study) with a non-synonymous variant 
(rs8192284, also annotated as rs2228145, which did not 
meet our initial selection criteria) previously reported to 
be associated with increased proteolytic cleavage of the 
soluble IL6R from its membrane-bound form30,31 (see 
appendix p 26 for mechanistic details) and became our 
lead SNP for the analysis. Where rs7529229 was not 
genotyped, a proxy SNP was used (deﬁ ned on the basis of 
r²≥0·90 with rs7529229 in individuals of European 
ancestry; appendix pp 18–19). Information about 
rs4845371 and rs12740969 is reported in subsidiary 
analyses. 40 studies (133 449 participants) provided 
data for rs7529229, 18 studies (52 475 participants) for 
rs4845371, and 19 studies (59 126 participants) for 
rs12740969. All studies met the prespeciﬁ ed quality 
control threshold criteria for call rate, HWE, and MAF 
(appendix pp 18–19).
The IL6R rs7529229 SNP displayed additive associ-
ations with circulating concentrations of interleukin 6, 
C-reactive protein, and ﬁ brinogen (ﬁ gure 1, table). 
Circulating interleukin-6 concentration increased with 
each additional copy of the minor allele at rs7529229 
(relative increase in geometric mean log interleukin-6 
concentration per allele 9·45%, 95% CI 8·34–10·57; 
p=8·41×10–⁶⁸), whereas the concentrations of C-reactive 
protein and ﬁ brinogen decreased per minor allele 
(relative decrease in geometric mean log C-reactive 
protein 8·35%, 95% CI 7·31–9·38, and ﬁ brinogen 
0·85%, 0·60–1·10, per minor allele). The associations 
with interleukin 6 and C-reactive protein were 
consistent across study-speciﬁ c subgroups (appendix 
pp 34–37) with no evidence of genotype-by-subgroup 
interaction (p>0·05 for all analyses). Concentration of 
soluble IL6R increased per minor allele (table). The 
functional rs8192284 variant showed associations with 
interleukin 6, C-reactive protein, and ﬁ brinogen that 
were directionally concordant with those of rs7529229 
in the Whitehall II study (appendix p 24). No signiﬁ -
cant association was noted between the rs7529229 
SNP and concentration of total, LDL, and HDL 
cholesterol or tri glycerides in analyses including up to 
114 615 indiv iduals (table).
Figure 1: Association of the IL6R rs7529229 variant with (A) interleukin 6, 
(B) C-reactive protein, and (C) ﬁ brinogen concentration
Estimates are based on pairwise comparison of individuals heterozygous or 
homozygous for the variant T allele with reference to the CC homozygous group. 
The total number of studies and participants are also shown. Error bars show 
95% CIs.
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The blood markers interleukin 6, soluble IL6R, C-reactive 
protein, ﬁ brinogen, and total, LDL, and HDL cholesterol 
were available in both genetic studies and tocilizumab 
treatment trials allowing a direct comparison of IL6R 
genotype and IL6R blockade (table). The minor allele of 
rs7529229 and treatment with tocilizumab showed 
directionally concordant eﬀ ects; each was associated with 
reduced C-reactive protein and ﬁ brinogen and increased 
interleukin 6 and soluble IL6R (table, ﬁ gure 2). Tocilizumab 
treatment increased circulating total, HDL, and LDL 
cholesterol, and triglycerides, but the IL6R rs7529229 
SNP, by contrast, showed no signiﬁ cant association with 
any of these lipid fractions (table, ﬁ gure 2). In randomised 
trials, tocilizumab increased concentrations of albumin 
and haemoglobin and decreased erythrocyte sedimentation 
rate (ESR), platelet count, and serum amyloid A (table). 
The eﬀ ect of rs7529229 was directionally concordant with 
that of tocilizumab on albumin, haemoglobin, and platelet 
count (table, ﬁ gure 2). Data for ESR were unavailable in 
the genetic studies, but plasma viscosity (reﬂ ected by ESR) 
was lower in carriers of the rs7529229 minor allele (mean 
diﬀ erence per allele –2·16×10–³ mPa.s, 95% CI –3·86×10–⁴ 
to –3·94×10–³, p=0·02; ﬁ ve studies, 15 589 indi viduals). 
Absence of data for serum amyloid A in the genetic 
analysis precluded comparison with tocilizumab treat-
ment. In comparison of tocilizumab treatment with the 
rs7529229 variant, the direction of eﬀ ect was concordant 
for nine of the ten biomarkers (table, ﬁ gure 2), and greater 
than expected under the null hypothesis of no concord-
ance (binomial test, p=0·01).
We also examined the association of IL6R variants 
with coronary heart disease. In a meta-analysis of 
34 studies (25 458 coronary heart disease cases, 
100 740 controls) the OR for the primary outcome (all 
fatal and non-fatal coronary heart disease events; 
appendix pp 15–16) per minor allele at rs7529229 was 
0·95 (95% CI 0·93–0·97, p=1·53×10–⁵). There was low 
heterogeneity between studies (I²=10%, 95% CI 0–41) 
and the eﬀ ect estimates were consistent in prospective 
and case-control studies, including previously published 
data32 (ﬁ gure 3). In a subset of 97 300 individuals 
(27 studies) for whom relevant data were available, the 
association of rs7529229 with the primary outcome 
(14 360 cases and 82 940 con trols) was consistent in 
stratiﬁ ed analyses (appendix pp 1–7) with no evidence 
for eﬀ ect modiﬁ cation by any of these subgroups 
(appendix pp 40–41).
Associations of rs7529229 with risk of fatal or non-fatal 
stroke (OR 0·98, 95% CI 0·95–1·02, p=0·30) in 6904 cases 
and 90 512 controls (27 studies) and with fatal or non-fatal 
cardiovascular disease events combined (OR 0·98, 
95% CI 0·95–1·00, p=0·05) in 17 595 cases and 
76 321 controls (26 studies) were suggestive but not 
compelling (ﬁ gure 4). Up to three of six randomised trials 
of tocilizumab reported the incidence of cardiac or 
vascular events, or both, with median follow-up of 
24 weeks (appendix pp 22–23). However, imprecise 
endpoint deﬁ nition and the small number of events 
prevented comparison with genetic studies.
In an analysis of safety endpoints in tocilizumab trials, 
data suggested an increased risk of infection (OR 1·30, 
95% CI 1·07–1·58) and increased concentrations of 
hepatic enzymes alanine transaminase and aspartate 
transaminase (table) with tocilizumab treatment com-
pared with placebo (appendix pp 22–23). By contrast 
with evidence for tocilizumab, genetic analyses (although 
in a relatively small subset) did not reveal any association 
with concentrations of aspartate transaminase (table) or 
in log γ-glutamyl transferase (relative diﬀ erence in 
geometric mean per allele –0·64%, 95% CI –1·95 to 0·69, 
p=0·34; seven studies, 15 641 individuals). Our genetic 
experiment did not include infection as an outcome and 
published evidence for the IL6R rs7529229 variant 
was scarce.33 Genome-wide association studies of 
tuberculosis34 and meningococcal disease35 have not 
reported associations of variants in IL6R with risk of 
those outcomes.
Neither the evidence from tocilizumab trials nor the 
genetic studies to date have suggested an association of 
IL6R blockade with increased risk of cancer. The pooled 
OR for development of any cancer was 0·42 (95% CI 
0·06–2·88; four cases and 1196 controls) for tocilizumab 
treatment in randomised trials, and was 0·98 (95% CI 
0·93–1·03; 5376 cases and 57 123 controls) for the IL6R 
rs7529229 variant. In published genome-wide association 
studies and new look-ups, the IL6R rs7529229 variant 
showed no association with breast cancer (OR 1·01, 
Figure 2: Associations of the minor allele of the IL6R SNP rs7529229 and tocilizumab (8 mg/kg) versus 
placebo with commonly reported biomarkers
Concordance between the drug and genetic variants is shown. Eﬀ ects are presented as standardised mean diﬀ erence 
apart from loge transformed variables (shown by *), for which rs7529229 eﬀ ects represent the mean diﬀ erence on 
the log scale. Estimates for soluble interleukin-6 receptor were not plotted since their substantially greater 
magnitude would disrupt the scale of the graph: standardised mean diﬀ erences were 0·75 (95% CI 0·59–0·91) ng/mL 
per minor allele for rs7529229, and 93·67 (95% CI 90·27–97·06) ng/mL for tocilizumab 8 mg/kg versus placebo. 
SNP=single nucleotide polymorphism.
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95% CI 0·94–1·10) or colorectal cancer (OR 1·03, 95% CI 
0·96–1·12; ﬁ gure 4; appendix p 17).
The IL6R rs7529229 variant was associated with 
lowered systolic blood pressure (per-allele β coeﬃ  cient 
–0·21 mm Hg, 95% CI –0·37 to –0·05, p=0·01) 
and diastolic blood pressure (per-allele β coeﬃ  cient 
–0·11 mm Hg, 95% CI –0·20 to –0·02, p=0·02) in 
33 studies (112 979 individuals). There was suggestive 
evidence that the rs7529229 variant was associated with 
reduced risk of type 2 diabetes (OR 0·97, 95% CI 
0·94–1·00, p=0·06) in 12 859 cases and 86 807 controls 
(ﬁ gure 4), although this exploratory ﬁ nding needs 
further investigation.
Discussion
Our study provides strong evidence in human beings 
for a causal role of a speciﬁ c inﬂ am matory mechanism 
(ie, IL6R signalling) in coronary heart disease (panel). A 
common polymorphism in IL6R marking a non-
synonymous variant (p.Asp358Ala) with known func-
tional consequences30,36 was associated with diﬀ erences in 
circulating concentrations of soluble IL6R, interleukin 6, 
Figure 3: Association of IL6R rs7529229 with risk of fatal and non-fatal coronary heart disease
Individual study odds ratios were based on a per-allele model and pooled with ﬁ xed eﬀ ects meta-analysis. *Data published in reference 30. †Data published in 
reference 32.
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C-reactive protein, and ﬁ brinogen that were directionally 
concordant with those reported in trials of IL6R blockade 
with tocilizumab. Meta-analysis of 34 studies including 
25 458 coronary heart disease cases and 100 740 controls 
suggested the same IL6R rs7529229 variant was associ-
ated with reduced odds of coronary heart disease events. 
This ﬁ nding suggests that targeting of IL6R could provide 
a novel therapeutic approach to prevention of coronary 
heart disease.
Although the IL6R rs7529229 variant was associated with 
reduced circulating C-reactive protein and ﬁ brinogen 
concentrations, this study should not be interpreted as a 
mendelian randomisation analysis investigating causality 
of C-reactive protein or ﬁ brinogen in coronary heart 
disease. Previous large mendelian randomisation studies 
using SNPs in the genes encoding C-reactive protein and 
ﬁ brinogen6,7,32,37–39 suggested that neither is a causal media-
tor of coronary heart disease. Therefore, other consequences 
of reduced interleukin-6 signalling could be responsible 
for the association with decreased risk of coronary heart 
disease that we identiﬁ ed. Speciﬁ c mendelian random-
isation analyses for interleukin 6 have not yet been done, 
largely because SNPs in the gene encoding interleukin 6 
(IL6, Ch7p15.3) that reliably associate with circulating 
interleukin-6 concentration have not been identiﬁ ed.40,41 By 
contrast, the present study provides an example of a 
diﬀ erent type of mendelian randomisation analysis: one 
used to validate a drug target.
Although the association of the IL6R variant with 
raised concentrations of interleukin 6 and reduced 
coronary risk noted in this study might seem paradoxical, 
the pattern is consistent with pharmacological blockade 
of IL6R with tocilizumab. The ﬁ nding can be explained 
by reduced IL6R signalling in carriers of the variant 
allele, which leads to attenuation of downstream 
consequences of interleukin 6 (of which a reduction in 
C-reactive protein and ﬁ brinogen concentrations are but 
two), and an accumulation or release of feedback 
inhibition of the upstream ligand (interleukin 6) and its 
soluble receptor.42
Randomised trials of tocilizumab in patients with 
rheumatoid arthritis reported increases in blood lipid 
fractions.15,16 By contrast, carriage of the IL6R rs7529229 
minor allele was not associated with changes in any 
major blood lipid fraction. Evidence suggesting 
individuals carrying the rs7529229 variant were more 
likely to use lipid-lowering drugs than were non-carriers 
was weak (OR per minor allele 1·02, 95% CI 0·99–1·06, 
p=0·24); the absence of association with blood lipids was 
consistent between users and non-users of these drugs 
(heterogeneity χ² p=0·15).
There are several potential explanations for the dis-
cordance in eﬀ ects on blood lipids between tocilizumab 
treatment and IL6R genotype. First, random ised trials of 
tocilizumab were done in patients who had higher levels 
of background inﬂ ammation (baseline mean C-reactive 
protein 28·4 mg/L) than did participants in the genetic 
studies sampled from general populations (geometric 
mean C-reactive protein 1·8 mg/L). The eﬀ ects of 
tocilizumab on lipids might be mechanism-based but 
only manifest on a background of substantial systemic 
inﬂ ammation (which, in many conditions, is associated 
with reduced circulating lipid concentration43) and there-
fore not detectable at low levels of inﬂ ammation seen in 
healthy individuals. Second, there might be diﬀ erences 
between the lifelong eﬀ ect of genetic variants in IL6R and 
the short-term, later-life exposure to tocilizumab. Third, 
the eﬀ ect of pharmacological blockade and genetic 
variation on classic signalling through the membrane-
bound IL6R versus trans-signalling via the soluble 
receptor might also diﬀ er. Tocilizumab binds both the 
soluble and membrane-bound receptors inhibiting 
classical and trans path ways,44,45 but the functional poly-
morphism tagged by rs7529229 (rs8192284) results in 
increased soluble IL6R concentration through increased 
proteolytic cleavage of the membrane-bound receptor46–48 
Figure 4: Association of IL6R rs7529229 with secondary and safety endpoints
Summary per-allele odds ratio for cardiovascular and non-cardiovascular endpoints for the IL6R rs7529229 variant. Individual study odds ratios were based on a 
per-allele model in the present collaborative analysis and genome-wide association studies and pooled with ﬁ xed eﬀ ects meta-analysis. CHD=coronary heart disease. 
CVD=cardiovascular disease.
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and possibly a reduction in the number of functioning 
membrane-bound receptors.30,36 Membrane-bound IL6R 
mediates interleukin-6 signalling in hepatocytes and 
some leucocyte populations, whereas the soluble receptor 
acts on a diverse range of cell types including mega-
karyocytes and endothelial cells;2,48 both mechanisms rely 
on the ubiquitously expressed signal transducer, gp130. 
IL6R-mediated eﬀ ects on blood lipids might also need a 
suprathreshold change in IL6R signalling, which might 
be achieved by pharmacological inhibition but not by 
natural genetically-mediated changes in the concen tration 
or function of the IL6R. Finally, the possibility remains 
that the lipid-related eﬀ ects of tocilizumab are an oﬀ -
target action.
The association of the IL6R rs7529229 variant with 
lowered risk of coronary heart disease provides robust 
evidence of a role for inﬂ ammation in pathogenesis of 
coronary heart disease that is consistent with previously 
reported ﬁ ndings based on the IL6R rs4537545 SNP (in 
LD with rs7529229, r²=1·00),32 although our analysis 
included more than twice the number of cases. The eﬀ ect 
estimates obtained from our de-novo analysis of largely 
prospective studies and the previous analysis based 
mainly on case-control studies were highly consistent 
with no evidence of heterogeneity in the eﬀ ect estimates 
obtained from prospective, case-control, or cross-sectional 
studies. Furthermore, we did not identify heterogeneity 
in the genetic eﬀ ects in individuals stratiﬁ ed by prevailing 
concentrations of non-HDL cholesterol or by lipid-
lowering drug use, generating the hypothesis that the 
eﬀ ects of IL6R blockade could be additive to those of 
established lipid-based interventions.
The randomised trials of tocilizumab designed to 
examine drug eﬃ  cacy in rheumatoid arthritis were fairly 
small and of short duration. Cardiac and vascular safety 
endpoints were reported as part of the safety assessment, 
but only one trial28 reported myocardial infarctions. 
Absence of detail on the deﬁ nitions of safety outcomes in 
the remaining randomised trials made assessment of the 
eﬀ ect of tocilizumab on risk of coronary events too 
imprecise to be valuable. Infections were the most 
commonly reported adverse events in tocilizumab trials.15 
We lacked data for infectious events in the genetic 
studies; however, published evidence from candidate 
gene studies have not suggested an IL6R association with 
risk of respiratory infection.33 Risk of incident infection 
would be an important safety consideration in any trial of 
IL6R inhibition for prevention of coronary heart disease.
In addition to increases in blood lipids, there were 
infrequent reports of raised hepatic enzymes in trials of 
tocilizumab, although the magnitude of these changes did 
not increase with prolonged exposure.15 We noted no 
association of the lead IL6R SNP with aspartate trans-
aminase. Analysis of data from genetic studies in this 
collaboration and those reported in the literature (including 
genome-wide association studies and other large-scale 
studies) did not reveal increased risk of common cancers. 
Our safety proﬁ ling of IL6R blockade in the genetic 
experiment included the eﬀ ect of IL6R variants on 
established cardiovascular risk factors such as type 2 
diabetes and blood pressure. The ﬁ ndings were suggestive 
of associations of the rs7529229 SNP with reduced risk of 
type 2 diabetes and lowered systolic and diastolic pressures, 
although these need further investigation.
This large-scale analysis provides reliable genetic 
evidence for the role of a speciﬁ c inﬂ ammatory pathway 
in the development of coronary heart disease in humans. 
Comparison of the genetic ﬁ ndings with data from 
randomised trials of tocilizumab supports further 
evaluation of IL6R inhibition as a therapeutic strategy for 
prevention of coronary heart disease. Other mono clonal 
Panel: Research in context
Systematic review
We searched Medline via PubMed for “tocilizumab AND 
(“coronary heart disease” OR “myocardial infarction”), for 
“interleukin-6 receptor AND (“coronary heart disease” OR 
“myocardial infarction”), and for “IL6R” AND (“coronary heart 
disease” OR “myocardial infarction”) up to Jan 8, 2012. Local 
and systemic inﬂ ammation is implicated in atherosclerosis but, 
as yet, there are no licensed approaches for prevention of 
cardiovascular disease that target inﬂ ammatory mechanisms. 
Mendelian randomisation studies suggest that two intensively 
studied biomarkers of inﬂ ammation associated with 
cardiovascular disease, C-reactive protein and ﬁ brinogen, are 
unlikely to be causally related to athero sclerosis. High 
circulating interleukin-6 concentration is associated with 
increased risk of coronary heart disease in observational studies 
and preliminary evidence suggests a variant in the gene for its 
receptor (IL6R) might be associated with reduced risk of 
coronary heart disease.31 Tocilizumab, a monoclonal antibody 
targeting the interleukin-6 receptor (IL6R), is licensed for 
treatment of rheumatoid arthritis, but whether IL6R blockade 
reduces risk of coronary heart disease is unknown.
Interpretation
Applying the mendelian randomisation principle, we found 
that a variant in the IL6R gene had eﬀ ects on biomarkers of 
inﬂ ammation and related pathways (including interleukin 6, 
C-reactive protein, ﬁ brinogen, haemoglobin, albumin, and 
others) that are directionally concordant with those of 
tocilizumab treatment reported by randomised trials. In 
keeping with that expected for common alleles, the size of 
the genetic eﬀ ect was small compared with that of the drug. 
Nevertheless, the same genetic variant was associated with a 
lowered risk of coronary heart disease in a sample of 
25 458 coronary heart disease cases and 100 740 controls 
(odds ratio per minor allele 0·95, 95% CI 0·93–0·97, 
p=1·53×10⁵). This mendelian randomisation analysis 
suggests that IL6R signalling is involved in coronary heart 
disease and that the IL6R could be a valuable target for the 
prevention or treatment of coronary heart disease.
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antibodies against IL6R are now in advanced development 
and small molecules with activity at IL6R have also been 
reported.49 An ongoing trial of the anti-interleukin-1β 
monoclonal antibody canakinumab for reduction of 
coronary heart disease risk (NCT01327846) underlines 
the potential of inﬂ ammatory pathways as targets for 
cardiovascular prevention and supports a need for a trial 
of IL6R inhibition for prevention of coronary heart 
disease events.
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